Category - Developments

Developments

Akebia Therapeutics vadadustat meets primary endpoint in two Phase 3 trials

Akebia Therapeutics (NASDAQ:AKBA) vadadustat met its primary endpoint in two pivotal Phase 3 clinical trials for anemia due to chronic kidney disease (CKD). The trials compared the safety and efficacy of vadadustat to...

March 13, 2019

Developments

Akari Therapeutics announces successful pre-IND FDA meeting for Coversin

Akari Therapeutics (NASDAQ:AKTX) had a positive pre-IND meeting with the FDA about its proposed pivotal clinical trial program for Coversin for the treatment of pediatric hematopoietic stem cell transplant-related...

March 13, 2019

Developments

EyePoint Pharma launches DEXYCU intraocular suspension in U.S.

EyePoint Pharmaceuticals (NASDAQ:EYPT) commercially launched DEXYCU in the U.S. as the first and only FDA-approved intraocular steroid for the treatment of postoperative inflammation. DEXYCU is administered as a single...

March 13, 2019

Developments

FDA clears Aerie Pharma’s Rocklatan in glaucoma or ocular hypertension

The FDA approved Aerie Pharmaceuticals’ (NASDAQ:AERI) Rocklatan ophthalmic solution to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Aerie, which launched Rhopressa in...

March 13, 2019

Developments

Neurocrine Biosciences reports positive Phase 2 congenital adrenal hyperplasia data

Neurocrine Biosciences (NASDAQ:NBIX) announced positive interim results from its Phase 2 proof-of-concept study evaluating NBI-74788 in adult patients with classic congenital adrenal hyperplasia (CAH). Classic CAH is a...

March 12, 2019

Developments

Seres Therapeutics in microbiome immuno-oncology collaboration with AstraZeneca

Seres Therapeutics (NASDAQ:MCRB) entered a three-year research collaboration with AstraZeneca to focus on advancing the understanding of the microbiome in augmenting the efficacy of cancer immunotherapy, including...

March 11, 2019

Developments

Zafgen pulls IND application for Prader-Willi Syndrome candidate; CMO resigns

Zafgen (NASDAQ:ZFGN) has suspended plans to file an IND for its Prader-Willi Syndrome candidate after recently observing muscle degeneration and other anomalies in rodent toxicology studies. The effects were observed in...

March 11, 2019

Developments

Zynerba Pharmaceuticals initiates Phase 2 trial of CBD gel for autism spectrum disorder

Zynerba Pharmaceuticals (NASDAQ:ZYNE) initiated a Phase 2 trial to assess the safety, tolerability and efficacy of Zygel for the treatment of autism spectrum disorder (ASD). Zygel in a cannabidiol-based gel that...

March 11, 2019

Developments

Seelos Therapeutics acquires exclusive license to Parkinson’s disease therapy

Seelos Therapeutics (NASDAQ:SEEL) acquired an exclusive license to a family of peptide inhibitors that target the aggregation of alpha-synuclein, a protein implicated in Parkinson’s disease (PD). Seelos will develop the...

March 8, 2019

Developments

Tonix Pharmaceuticals receives new European use patent for PTSD drug

Tonix Pharmaceuticals (NASDAQ:TNXP) received a new European use patent for TNX-601, providing intellectual property protection until 2029 for the treatment of neurocognitive dysfunction associated with corticosteroids...

March 8, 2019

Category - Developments

Subscribe